Ding S F, Habib N A, Dooley J, Wood C, Bowles L, Delhanty J D
Department of Surgery, Royal Free Hospital School of Medicine, London, UK.
Br J Cancer. 1991 Dec;64(6):1083-7. doi: 10.1038/bjc.1991.468.
Suppressor gene loci involved in the development of hepatocellular carcinoma (HCC) have not been fully identified. The aim of this study was to look for consistent allele loss, or loss of heterozygosity (LOH), in HCC which might represent such gene loci. We have prepared DNA from tumour and non-tumour material from 16 patients with HCC (nine with and seven without liver cirrhosis). Tumour DNA was compared with non-tumour DNA by Southern analysis performed with a panel of 22 probes recognising restriction fragment length polymorphisms assigned to chromosomes 1, 4, 5, 7, 9, 11, 12, 13, 14, 16, 17, 18 and 20. Non-tumour DNA from five of the seven patients with HCC without cirrhosis was heterozygous with the probe Lambda MS8 (5q35-qter), and in all five there was LOH in tumour DNA. Probes for other regions of chromosome 5 have as yet shown no LOH in this group of patients. Cirrhotic HCC patients exhibited LOH on chromosomes 1q and 5p but not in the region 5q35-qter. Both groups of HCC showed LOH on chromosome 17p13. Screening with other probes has not shown any consistent LOH in either group as yet. A comparison of LOH on chromosome 5 in seven patients with colorectal metastasis in the liver showed a different pattern, which suggests that the proposed tumour suppressor gene locus for HCC without cirrhosis on chromosome 5 appears to be distinct from the familial adenomatous polyposis coli gene.
参与肝细胞癌(HCC)发生发展的抑癌基因位点尚未完全明确。本研究的目的是在HCC中寻找可能代表此类基因位点的一致性等位基因缺失或杂合性缺失(LOH)。我们从16例HCC患者(9例有肝硬化,7例无肝硬化)的肿瘤组织和非肿瘤组织中提取了DNA。通过用一组22个探针进行Southern分析,将肿瘤DNA与非肿瘤DNA进行比较,这些探针可识别定位于染色体1、4、5、7、9、11、12、13、14、16、17、18和20上的限制性片段长度多态性。7例无肝硬化的HCC患者中有5例的非肿瘤DNA与探针Lambda MS8(5q35 - qter)呈杂合状态,且这5例患者的肿瘤DNA均存在LOH。针对染色体5其他区域的探针在该组患者中尚未显示出LOH。肝硬化HCC患者在染色体1q和5p上出现LOH,但在5q35 - qter区域未出现。两组HCC在染色体17p13上均出现LOH。用其他探针进行筛查,目前在两组中均未显示出任何一致性的LOH。对7例肝内有大肠转移的患者染色体5上的LOH进行比较,结果显示出不同的模式,这表明所提出的无肝硬化HCC在染色体5上的肿瘤抑制基因位点似乎与家族性腺瘤性息肉病基因不同。